参考文献/References:
[1] Horowitz M,Flint A,Jones KL,et al.Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes[J].Diabetes Res Clin Pract,2012,97(2):258-266.DOI:10.1016/j.diabres.2012.02.016.
[2] Dalle S,Burcelin R,Gourdy P.Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes[J].Cell Signal,2013,25(2):570-579.DOI:10.1016/j.cellsig.2012.11.009.
[3] Chaabane C,Otsuka F,Virmani R,et al. Biological responses in stented arteries[J].Cardiovasc Res,2013,99(2):353-363.DOI:10.1093/cvr/cvt115.
[4] Muto A,Fitzgerald TN,Pimiento JM,et al.Smooth muscle cell signal transduction: implications of vascular biology for vascular surgeons[J].J Vasc Surg,2007,45 Suppl A:A15-A24.DOI:10.1016/j.jvs.2007.02.061.
[5] Grudzinska MK,Bojakowski K,Soin J,et al. RCMV increases intimal hyperplasia by inducing inflammation, MCP-1 expression and recruitment of adventitial cells to intima[J].Herpesviridae,2010,1(1):7.DOI:10.1186/2042-4280-1-7.
[6] Eriksson L,Saxelin R,Röhl S,et al.Glucagon-like peptide-1 receptor activation does not affect re-endothelialization but reduces intimal hyperplasia via direct effects on smooth muscle cells in a nondiabetic model of arterial injury[J].J Vasc Res,2015,52(1):41-52.DOI:10.1159/000381097.
[7] Goto H,Nomiyama T,Mita T,et al.Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury[J].Biochem Biophys Res Commun,2011,405(1):79-84.DOI:10.1016/j.bbrc.2010.12.131.
[8] Hirata Y,Kurobe H,Nishio C,et al.Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury[J].Eur J Pharmacol,2013,699(1-3):106-111.DOI:10.1016/j.ejphar.2012.11.057.
[9] Erdogdu Ö,Eriksson L,Nyström T,et al.Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells[J].Biochem Biophys Res Commun,2012,419(4):790-795.DOI:10.1016/j.bbrc.2012.02.106.
[10] Arakawa M,Mita T,Azuma K,et al.Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4[J].Diabetes,2010,59(4):1030-1037.DOI:10.2337/db09-1694.
[11] 吴杰萍, 郭志新,齐伟,等. 艾塞那肽通过下调p22phox、NOX4和TGF-β1减轻1型糖尿病大鼠主动脉的氧化应激损伤[J]. 中国动脉硬化杂志, 2013, 21(8):711-715.
[12] Mehta PK, Griendling KK. Angiotensin Ⅱ cell signaling: physiological and pathological effects in the cardiovascular system[J]. Am J Physiol Cell Physiol, 2007, 292(1):C82-C97. DOI:10.1152/ajpcell.00287.2006.
[13] Nagayama K,Kyotani Y,Zhao J,et al.Exendin-4 prevents vascular smooth muscle cell proliferation and migration by angiotensin Ⅱ via the inhibition of ERK1/2 and JNK signaling pathways[J].PLoS One,2015,10(9):e0137960.DOI:10.1371/journal.pone.0137960.
[14] Muñoz FJ,Jiménez M,Melón J,et al. Phenotypic changes in vascular smooth muscle cells during aging: insulin effect on migration[J].Gerontology,1998,44(3):149-152.
[15] Zhao L,Li AQ,Zhou TF,et al.Exendin-4 alleviates angiotensin Ⅱ-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway[J].Am J Physiol Cell Physiol,2014,307(12):C1130-C1141. DOI:10.1152/ajpcell.00151.2014.
[16] Zhou T,Zhang M,Zhao L,et al.Activation of Nrf2 contributes to the protective effect of Exendin-4 against angiotensin Ⅱ-inducedvascular smooth muscle cell senescence[J].Am J Physiol Cell Physiol,2016,311(4):C572-C582.DOI:10.1152/ajpcell.00093.2016.
[17] Bakowski D,Nelson C,Parekh AB. Endoplasmic reticulum-mitochondria coupling: local Ca2+ signalling with functional consequences[J].Pflugers Arch,2012,464(1):27-32.DOI:10.1007/s00424-012-1095-x.
[18] Wang PT,Garcin PO,Fu M,et al. Distinct mechanisms controlling rough and smooth endoplasmic reticulum contacts with mitochondria[J].J Cell Sci,2015,128(15):2759-2765.DOI:10.1242/jcs.171132.
[19] Lim JH,Lee HJ,Ho Jung M,et al.Coupling mitochondrial dysfunction to endoplasmic reticulum stress response: a molecular mechanism leading to hepatic insulin resistance[J].Cell Signal,2009,21(1):169-177.DOI:10.1016/j.cellsig.2008.10.004.
[20] Ahn SY,Choi YS,Koo HJ,et al. Mitochondrial dysfunction enhances the migration of vascular smooth muscles cells via suppression of Akt phosphorylation[J].Biochim Biophys Acta,2010,1800(3):275-281.DOI:10.1016/j.bbagen.2009.09.005.
[21] Morales PE,Torres G,Sotomayor-Flores C,et al.GLP-1 promotes mitochondrial metabolism in vascular smooth muscle cells by enhancing endoplasmic reticulum-mitochondria coupling[J].Biochem Biophys Res Commun,2014,446(1):410-416. DOI:10.1016/j.bbrc.2014.03.004.
[22] Wang L,Yu T,Lee H,et al.Decreasing mitochondrial fission diminishes vascular smooth muscle cell migration and ameliorates intimal hyperplasia[J].Cardiovasc Res,2015,106(2):272-283.DOI:10.1093/cvr/cvv005.
[23] Torres G,Morales PE,García-Miguel M,et al. Glucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulation[J].Biochem Pharmacol,2016,104:52-61.DOI:10.1016/j.bcp.2016.01.013.
相似文献/References:
[1]姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
Yao Hong*,Xi Guangxia,Guo Min,et al.The distributions and functions of glucagon like peptide-1 and its receptors in the central nervous system[J].International Journal of Endocrinology and Metabolism,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
[2]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(01):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
[3]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(01):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[4]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[5]吴海洋,黄祯子,彭嘉欣,等.胰高血糖素样肽-1与肾素-血管紧张素系统的交互作用[J].国际内分泌代谢杂志,2016,36(05):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
Wu Haiyang,Huang Zhen-zi,Peng Jiaxin,et al.Interaction between glucagon-like peptide-1 and renin angiotensin system[J].International Journal of Endocrinology and Metabolism,2016,36(01):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
[6]韩丽萍,陈莉明.GLP-1的神经保护作用[J].国际内分泌代谢杂志,2016,36(05):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
Han Liping,Chen Liming.Neuroprotective actions of glucagon-like peptide-1[J].International Journal of Endocrinology and Metabolism,2016,36(01):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
[7]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(01):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[8]阮莹莹 闫彩凤.GLP-1对2型糖尿病患者骨骼的影响[J].国际内分泌代谢杂志,2018,38(04):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
Ruan Yingying,Yan Caifeng..The impact of GLP-1 on bone in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(01):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
[9]史雨清,杨昱,李宸,等.Tirzepatide:一种新型GLP-1/GIP双受体激动剂[J].国际内分泌代谢杂志,2021,41(06):645.[doi:10.3760/cma.j.cn121383-20200924-09046]
Shi Yuqing,Yang Yu,Li Chen,et al.Tirzepatide:a novel GLP-1/GIP dual receptor agonist[J].International Journal of Endocrinology and Metabolism,2021,41(01):645.[doi:10.3760/cma.j.cn121383-20200924-09046]